10x Genomics, Inc. (LON:0A88)

10x Genomics Statistics

Total Valuation

10x Genomics has a market cap or net worth of GBP 1.85 billion. The enterprise value is 1.56 billion.

Market Cap	1.85B
Enterprise Value	1.56B

Important Dates

The next estimated earnings date is Thursday, February 12, 2026.

Earnings Date	Feb 12, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	116.47M
Shares Outstanding	n/a
Shares Change (YoY)	+3.07%
Shares Change (QoQ)	+0.80%
Owned by Insiders (%)	8.14%
Owned by Institutions (%)	97.15%
Float	114.31M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	3.87
PB Ratio	3.17
P/TBV Ratio	3.47
P/FCF Ratio	30.45
P/OCF Ratio	28.08
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-27.47
EV / Sales	3.32
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	25.68

Financial Position

The company has a current ratio of 4.48, with a Debt / Equity ratio of 0.11.

Current Ratio	4.48
Quick Ratio	3.93
Debt / Equity	0.11
Debt / EBITDA	n/a
Debt / FCF	1.07
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -10.12% and return on invested capital (ROIC) is -9.85%.

Return on Equity (ROE)	-10.12%
Return on Assets (ROA)	-8.42%
Return on Invested Capital (ROIC)	-9.85%
Return on Capital Employed (ROCE)	-15.04%
Weighted Average Cost of Capital (WACC)	15.70%
Revenue Per Employee	365,598
Profits Per Employee	-43,474
Employee Count	1,306
Asset Turnover	0.65
Inventory Turnover	2.56

Taxes

In the past 12 months, 10x Genomics has paid 2.40 million in taxes.

Income Tax	2.40M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +35.06% in the last 52 weeks. The beta is 2.18, so 10x Genomics's price volatility has been higher than the market average.

Beta (5Y)	2.18
52-Week Price Change	+35.06%
50-Day Moving Average	18.55
200-Day Moving Average	13.51
Relative Strength Index (RSI)	50.36
Average Volume (20 Days)	3,773

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	6.09

Income Statement

In the last 12 months, 10x Genomics had revenue of GBP 477.47 million and -56.78 million in losses. Loss per share was -0.46.

Revenue	477.47M
Gross Profit	329.19M
Operating Income	-98.49M
Pretax Income	-54.38M
Net Income	-56.78M
EBITDA	-72.53M
EBIT	-98.49M
Loss Per Share	-0.46

Balance Sheet

The company has 358.64 million in cash and 64.71 million in debt, with a net cash position of 293.93 million.

Cash & Cash Equivalents	358.64M
Total Debt	64.71M
Net Cash	293.93M
Net Cash Per Share	n/a
Equity (Book Value)	584.08M
Book Value Per Share	4.62
Working Capital	381.27M

Cash Flow

In the last 12 months, operating cash flow was 65.86 million and capital expenditures -5.11 million, giving a free cash flow of 60.74 million.

Operating Cash Flow	65.86M
Capital Expenditures	-5.11M
Free Cash Flow	60.74M
FCF Per Share	n/a

Margins

Gross margin is 68.94%, with operating and profit margins of -20.63% and -11.89%.

Gross Margin	68.94%
Operating Margin	-20.63%
Pretax Margin	-11.39%
Profit Margin	-11.89%
EBITDA Margin	-15.19%
EBIT Margin	-20.63%
FCF Margin	12.72%

Dividends & Yields

10x Genomics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.07%
Shareholder Yield	-3.07%
Earnings Yield	-3.07%
FCF Yield	3.28%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

10x Genomics has an Altman Z-Score of 2.6 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.6
Piotroski F-Score	3